17 March 2026: The Association of Multisite Research Corporations (AMRC) today announces that Panthera and ObjectiveHealth have joined the organisation, bringing total membership to 19 multisite clinical research corporations (MCRCs), up from 14 members just 12 months ago.
This continued growth reflects increasing industry recognition that multisite organisations play a central role in delivering consistent, scalable, and high-quality clinical trials, and that operational performance must be properly recognised as a core indicator of quality.
Jim Kremidas, Executive Director of AMRC, commented: “The growth of AMRC over the past year reflects a clear shift in how multisite organisations are viewed across the industry. MCRCs are not simply operational vendors — they are strategic partners capable of delivering consistency, predictability, governance, and workforce stability at scale.
“As we move into 2026, our focus is on ensuring that quality is defined and assessed in a way that reflects how trials are actually delivered in practice. By strengthening our membership with organisations like Panthera and ObjectiveHealth, we enhance our collective ability to define, evidence, and advance systemic quality across the clinical research ecosystem.”
Panthera is the UK’s leading independent Site Management Organisation (SMO), that recruits patients and runs clinical trials on behalf of pharma. It joins AMRC at a time when sponsors and CROs are increasingly seeking deeper, more strategic partnerships with multisite organisations.
Stuart Young, CEO of Panthera, said: “We’re proud for Panthera to be joining the Association of Multisite Research Corporations (AMRC) at a time when sponsors are increasingly looking for deeper, more strategic partnerships with research sites.
“Multisite organisations now play a critical role in defining what good looks like in clinical trial delivery — not just in speed or scale, but in consistent, measurable quality across geographies. At Panthera, we see quality as something that must be designed, embedded and delivered in the same way, every time, wherever a trial is run.
“AMRC brings together organisations that share a commitment to working alongside sponsors to raise standards, improve predictability and deliver clinical trials at scale with confidence. We’re pleased to be part of that community and to contribute to shaping how quality is defined and delivered globally.”
ObjectiveHealth partners with leading physicians to embed clinical trials directly into community-based practices.
Steve Clemons, ObjectiveHealth Chief Executive Officer, commented: “The real reason ObjectiveHealth joined AMRC is simple: when experienced leaders from across the industry come together with a shared goal of improving clinical trial execution, the potential is enormous.
“Many of us have faced the same challenges and successes, and when we collaborate openly, share best practices, and learn from both what works and what doesn’t, the entire industry benefits, from patients and physicians to sponsors, CROs, and research networks.”
With membership increasing by more than 35% in the past year, AMRC continues to expand its role as a dedicated advocate and interface between MCRCs, Sponsors, CROs, regulators, and patients, ensuring that multisite organisations are recognised for advancing clinical trial research through enhanced data quality, improved patient safety, and streamlined operation..
As outlined in its 2026 positioning paper, Innovation. Consistency. Longevity., AMRC’s advocacy focuses on addressing a persistent industry challenge: the gap between performance and the perception of quality in clinical research. While Sponsors and CROs consistently value speed, reliability, and data integrity, these operational strengths are not always recognised as indicators of quality.
In response, this year AMRC will champion a system-level understanding of quality, promote recognition of operational performance as a meaningful measure of quality, and develop trusted, anonymised benchmarks. The Association will also convene cross-industry working groups to define quality indicators and support more effective strategic partnerships between MCRCs, Sponsors, and CROs.
Ends
Notes to editors
Organisations interested in participating in AMRC’s 2026 working groups or learning more about membership are encouraged to contact info@amrc.org.
AMRC members
- Alcanza Clinical Research
- Alliance for Multispecialty Research (AMR)
- CenExel
- Centricity Research
- DM Clinical Research
- Evolution Research Group (ERG)
- Eximia Research
- Flourish
- Helios Clinical Research
- Headlands Research
- Javara
- K2 Medical Research
- IMA Clinical Research
- Objective Health
- Panthera
- Paradigm Clinical Research
- Rovia Clinical
- Tekton Research
- Velocity Clinical Research
About AMRC
The Association of Multisite Research Corporations (AMRC) is a nonprofit organization dedicated to advancing the use of multisite clinical research corporations in the global clinical trial ecosystem. Through advocacy, collaboration, and education, AMRC aims to transform clinical trials to improve patient outcomes, data quality, and operational efficiency. Visit amrc.org for more information.
About ObjectiveHealth
ObjectiveHealth partners with leading physicians to embed clinical trials directly into community-based practices. By providing the tools, infrastructure, and dedicated research staff needed to deliver high-quality studies, the organisation expands patient access to trials close to home while offering sponsors strong, practice-integrated research partnerships.
Its leadership team combines extensive clinical research experience with technology expertise to modernise trial delivery and improve patient access at scale. For more information, visit: https://objective.health/
About Panthera
- Panthera is the UK’s leading independent Site Management Organisation (SMO), specialising in patient recruitment and the delivery of clinical trials through a network of seven dedicated research clinics across the UK – and now expanding into Europe.
- Working in partnership with leading CROs and pharmaceutical companies, Panthera provides rapid, reliable access to millions of potential participants across the UK and now Europe, enabling fast and efficient patient recruitment.
- Founded by Dr Ian Smith MBE, a pioneer of the SMO model, Panthera builds on a proven approach to running high-quality clinical trials in dedicated research settings and has helped redefine clinical trial delivery in the UK.
- Recognised for speed, quality and reliability, Panthera helps sponsors accelerate study timelines and streamline the path to commercialisation. panthera-bio.com
Media Contact
Katie Evans
kevans@amrc.org
